Results 171 to 180 of about 269,940 (298)

Juvenile systemic lupus erythematosus complicated with posterior reversible encephalopathy syndrome: a case report and literature review. [PDF]

Orphanet J Rare Dis
Luo M, He H, Zhou Q, Chen L, Xia C, Yuan G, He F.   +6 more
europepmc   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome

Arthritis &Rheumatology, Accepted Article.
Background ATP is released from platelets through both degranulation and pannexin‐1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium‐dependent signaling. Objective To evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired thrombo‐inflammatory ...
Bruna de Moraes Mazetto Fonseca, Somanathapura K. NaveenKumar, Srilakshmi Yalavarthi, Kavya Sugur, Thalia G. Newman, Claire K. Hoy, Cyrus Sarosh, Jordan K. Schaefer, Ajay Tambralli, Jacqueline A. Madison, Yu Zuo, Fernanda Orsi, Michael Holinstat, Jason S. Knight   +13 more
wiley   +1 more source

Clinical, humanistic, and economic burden of systemic lupus erythematosus in the Kingdom of Saudi Arabia. [PDF]

Cost Eff Resour Alloc
Al-Jedai A, Al-Mudaiheem H, Ghanim NA, Eshmawi M, AlHomood I, Dhopte P, Ojeil R.   +6 more
europepmc   +1 more source

Systemic Lupus Erythematosus [PDF]

Proceedings of the Royal Society of Medicine, 1971
openaire   +2 more sources

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring

Arthritis &Rheumatology, Accepted Article.
Background Using hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg, Benoît Blanchet, Yann Nguyen, Fauzia Hollnagel, Ada Clarke, Michelle Petri, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang‐Cheol Bae, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Andreas Jönsen, Graciela S. Alarcón, Ronald F. Van Vollenhoven, Cynthia Aranow, Véronique Le Guern, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Søren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Julie Chezel, Alicja Puszkiel, Nathalie Costedoat‐Chalumeau   +42 more
wiley   +1 more source

Letter to the Editor regarding "Organ involvement and laboratory abnormalities associated with tuberculosis disease in systemic lupus erythematosus patients: a systematic review and meta-analysis". [PDF]

Ann Med
Yang Z, Bao J, Fan Y.
europepmc   +1 more source

Molecular stratification of antiphospholipid syndrome through integrative analysis of the whole‐blood RNA transcriptome

Arthritis &Rheumatology, Accepted Article.
Objective Antiphospholipid syndrome (APS) is a thrombo‐inflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)‐positive patients using whole‐blood transcriptomics.
Amala Ambati, Feiyang Ma, Katarina Kmetova, Sherwin Navaz, Claire K. Hoy, Cyrus Sarosh, Ajay Tambralli, Erika Navarro‐Mendoza, Johann E. Gudjonsson, J. Michelle Kahlenberg, Jacqueline A. Madison, Alí Duarte‐García, Jason S. Knight, Yu Zuo   +13 more
wiley   +1 more source

Xanthomatous Discoid Lupus Erythematosus: An Unusual Histopathological Variant and Review of Reported Cases. [PDF]

Cureus
Prasertsook S, Boonchai W, Pattanaprichakul P.   +2 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source